A
2.17
0.00 (0.00%)
| Previous Close | 2.17 |
| Open | 2.14 |
| Volume | 474,858 |
| Avg. Volume (3M) | 1,917,467 |
| Market Cap | 218,540,704 |
| Price / Book | 0.510 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 20 May 2025 |
| Diluted EPS (TTM) | -2.50 |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 18.10 |
| Operating Cash Flow (TTM) | -303.92 M |
| Levered Free Cash Flow (TTM) | -216.69 M |
| Return on Assets (TTM) | -29.73% |
| Return on Equity (TTM) | -44.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ACELYRIN, INC. | Bearish | Bearish |
AIStockmoo Score
-1.0
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.00 |
|
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.14% |
| % Held by Institutions | 105.48% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tybourne Capital Management (Hk) Ltd | 31 Dec 2024 | 2,906,629 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis |
| 21 Apr 2025 | Announcement | Alumis and ACELYRIN Announce Amended Merger Agreement |
| 04 Apr 2025 | Announcement | Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger |
| 04 Mar 2025 | Announcement | Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger |
| 04 Mar 2025 | Announcement | ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger |
| 20 Feb 2025 | Announcement | ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences |
| 06 Feb 2025 | Announcement | Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |